ProMIS Neurosciences is trading 5.55% down at $13.20 despite broader biotech and major U.S. indexes moving higher on September 3, 2026, with no clear catalyst identified.
- No company-specific announcement, filing, earnings update, analyst action, or other clear catalyst was identified for September 3.
- The latest company news concerns September conference participation; recent clinical and financial updates predate the move.
- The decline remains unexplained and is not clearly attributable to sector or global sentiment.